Employees Provident Fund Board’s Regeneron Pharmaceuticals REGN Stock Holding History

Employees Provident Fund Board’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-8,500	Closed	-$8.93M	–	87
2024 Q2	$8.93M	Hold	8,500	–	–	0.14%	70
2024 Q1	$8.18M	Sell	8,500 -500	-6%	-$475K	0.14%	68
2023 Q4	$7.9M	Hold	9,000	–	–	0.15%	59
2023 Q3	$7.41M	Buy	9,000 +1,500	+20%	+$1.18M	0.17%	62
2023 Q2	$5.39M	Buy	7,500 +1,500	+25%	+$1.16M	0.13%	70
2023 Q1	$4.93M	Buy	+6,000	New	+$4.53M	0.13%	70

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Employees Provident Fund Board's REGN Position: Q3 2024 in Review

Employees Provident Fund Board sold out of Regeneron Pharmaceuticals (REGN) in Q3 2024, closing a stake of 8,500 shares — an estimated $8.93M sold.

Employees Provident Fund Board first reported a position in REGN in Q1 2023 and held it in 6 quarters. The position peaked at $8.93M in Q2 2024. 1,388 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

Employees Provident Fund Board reported no remaining Regeneron Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Employees Provident Fund Board sold 8,500 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $8.93M.
Employees Provident Fund Board first reported a position in Regeneron Pharmaceuticals in Q1 2023 and held it in 6 quarters.
Employees Provident Fund Board's Regeneron Pharmaceuticals position peaked at $8.93M in Q2 2024.
1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on Employees Provident Fund Board's 13F filing for Q3 2024, filed 17 Mar 2026.